Versant Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Versant Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,024	Closed	-$20.6K	–	2806
2026 Q1	$20.6K	Hold	1,024	–	–	﹤0.01%	1803
2025 Q4	$16.5K	Hold	1,024	–	–	﹤0.01%	1748
2025 Q3	$12.5K	Hold	1,024	–	–	﹤0.01%	1840
2025 Q2	$11.6K	Buy	1,024 +45	+5%	+$550	﹤0.01%	1824
2025 Q1	$11.3K	Buy	979 +813	+490%	+$8.3K	﹤0.01%	1665
2024 Q4	$1.41K	Buy	+166	New	+$1.72K	﹤0.01%	2128

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Versant Capital Management's KALV Position: Q2 2026 in Review

Versant Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,024 shares — an estimated $20.6K sold.

Versant Capital Management first reported a position in KALV in Q4 2024 and held it in 6 quarters. The position peaked at $20.6K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Versant Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Versant Capital Management sold 1,024 KalVista Pharmaceuticals shares in Q2 2026, an estimated $20.6K.
Versant Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Versant Capital Management's KalVista Pharmaceuticals position peaked at $20.6K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.